Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cheniere Energy (LNG) vs Sanofi SA (SNY) Price & Performance

Cheniere EnergyTrade

Price performance (Past 24H)

Key statistics

Cheniere Energy vs Sanofi SA — how do they compare? Cheniere Energy trades at $278.18 (market cap $57.39B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 10 Days and Sanofi SA for 94 Days on average.

LNGSNY
Market Cap
$57.39B$95.18B
Volume
1,215,8352,995,646
Sector
EnergyHealth
52-Week High
$296.91$52.34
52-Week Low
$188.83$39.51
Typical Hold Time
10 Days94 Days
Enterprise Value
$82.85B$114.48B
Dividend Yield
0.8%6.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cheniere Energy

No Aura AI signal available yet.

Sanofi SA

Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.

While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LNG
48% Buy52% Sell
Avg holding period · 10 Days
SNY
35% Buy65% Sell
Avg holding period · 94 Days

Top news

Latest headlines on both assets

About Cheniere Energy

Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.

Read more on LNG →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →